Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novacyt Picks Up Bargain With Omega's Infectious Disease Unit

Executive Summary

Clinical diagnostics firm Novacyt's M&A growth strategy is underway with the company announcing a bargain deal to buy the infectious disease business of Omega Diagnostics.

You may also be interested in...

Novacyt Lands New US Supply Deal, Maps Path To Profitability

Novacyt is continuing its quest to reach profitability in 2018. The French diagnostics group has entered into a partnership with US lab Genesis Diagnostics to develop and supply molecular assay panels for a range of indications. The five-year deal is worth a minimum of $3m, but Novacyt said it expects the agreement to deliver more significant returns. 

Salvia Scores $31M To Develop Neurostimulation Therapy

The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.

Signifier Medical Addresses US Sleep Disorder Market With New Funds

Signifier Medical Technologies is ramping up commercialization of its technology solutions for patients with snoring and sleep disordered breathing conditions.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts